Scopus subject area
Best Cancer Research journals
233 Scopus-active journals are ranked in Cancer Research. All are listed below, ranked by CiteScore percentile — 58 of them sit in quartile Q1. Every title links to a full profile with Scopus, Web of Science, ABDC, DOAJ and open-access details.
| # | Journal | CiteScore | Percentile | Quartile | WoS | ABDC | OA |
|---|---|---|---|---|---|---|---|
| 1 | Nature Reviews Cancer | 96.2 | 99th | Q1 | SCIE | – | No |
| 2 | Signal Transduction and Targeted Therapy | 81.6 | 99th | Q1 | SCIE | – | Yes |
| 3 | Cancer Cell | 75.4 | 98th | Q1 | SCIE | – | No |
| 4 | Journal of Hematology and Oncology | 70.1 | 98th | Q1 | SCIE | – | Yes |
| 5 | Molecular Cancer | 55 | 98th | Q1 | SCIE | – | Yes |
| 6 | Seminars in Cancer Biology | 42 | 97th | Q1 | SCIE | – | No |
| 7 | Cancer Communications | 40.3 | 97th | Q1 | SCIE | – | Yes |
| 8 | Nature Cancer | 38.5 | 96th | Q1 | SCIE | – | No |
| 9 | JAMA Oncology | 32.6 | 96th | Q1 | SCIE | – | No |
| 10 | Journal of the National Cancer Center | 31.2 | 95th | Q1 | ESCI | – | Yes |
| 11 | Trends in Cancer | 30.8 | 95th | Q1 | SCIE | – | No |
| 12 | Drug Resistance Updates | 29.1 | 95th | Q1 | SCIE | – | No |
| 13 | Journal of Experimental and Clinical Cancer Research | 22.3 | 94th | Q1 | SCIE | – | Yes |
| 14 | Neuro-Oncology | 21.1 | 94th | Q1 | SCIE | – | No |
| 15 | Experimental Hematology and Oncology | 19.6 | 93rd | Q1 | SCIE | – | Yes |
| 16 | Leukemia | 19.2 | 93rd | Q1 | SCIE | – | No |
| 17 | Cell Death and Disease | 17.6 | 92nd | Q1 | SCIE | – | Yes |
| 18 | Clinical Cancer Research | 17.3 | 92nd | Q1 | SCIE | – | No |
| 19 | Cancer Research | 17 | 92nd | Q1 | SCIE | – | No |
| 20 | Journal for ImmunoTherapy of Cancer | 16.6 | 91st | Q1 | SCIE | – | Yes |
| 21 | Cancer and Metastasis Reviews | 16.3 | 91st | Q1 | SCIE | – | No |
| 22 | Cancer Letters | 15.4 | 90th | Q1 | SCIE | – | No |
| 23 | Angiogenesis | 14.3 | 90th | Q1 | SCIE | – | No |
| 24 | Journal of Clinical Oncology | 14.2 | 89th | Q1 | SCIE | – | No |
| 25 | Biochimica et Biophysica Acta - Reviews on Cancer | 14.1 | 89th | Q1 | SCIE | – | No |
| 26 | Oncogene | 14 | 89th | Q1 | SCIE | – | No |
| 27 | Blood Cancer Discovery | 13.9 | 88th | Q1 | ESCI | – | No |
| 28 | British Journal of Cancer | 13.9 | 88th | Q1 | SCIE | – | No |
| 29 | Cell Death Discovery | 13.2 | 87th | Q1 | SCIE | – | Yes |
| 30 | Cancer Immunology Research | 12.6 | 87th | Q1 | SCIE | – | No |
| 31 | Breast | 12.6 | 86th | Q1 | SCIE | – | Yes |
| 32 | Apoptosis | 12.4 | 86th | Q1 | SCIE | – | No |
| 33 | Journal of the National Cancer Institute | 12.3 | 86th | Q1 | SCIE | – | No |
| 34 | ESMO Open | 12 | 85th | Q1 | SCIE | – | Yes |
| 35 | Prostate Cancer and Prostatic Diseases | 11.9 | 85th | Q1 | SCIE | – | No |
| 36 | Gastric Cancer | 11.8 | 84th | Q1 | SCIE | – | No |
| 37 | Annual Review of Biomedical Data Science | 11.6 | 84th | Q1 | SCIE | – | No |
| 38 | Cancer Biology and Medicine | 11.5 | 83rd | Q1 | SCIE | – | Yes |
| 39 | Neoplasia (United States) | 11.4 | 83rd | Q1 | SCIE | – | Yes |
| 40 | Cancer Gene Therapy | 11.1 | 83rd | Q1 | SCIE | – | No |
| 41 | Oncogenesis | 11 | 82nd | Q1 | SCIE | – | Yes |
| 42 | European Journal of Cancer | 10.9 | 82nd | Q1 | SCIE | – | No |
| 43 | Cancer | 10.6 | 81st | Q1 | SCIE | – | No |
| 44 | Cancer Cell International | 10.5 | 81st | Q1 | SCIE | – | Yes |
| 45 | Tumour Virus Research | 10.5 | 80th | Q1 | ESCI | – | Yes |
| 46 | Cancer Drug Resistance | 10.3 | 80th | Q1 | ESCI | – | No |
| 47 | International Journal of Oncology | 10.2 | 80th | Q1 | SCIE | – | No |
| 48 | International Journal of Radiation Oncology Biology Physics | 10.1 | 79th | Q1 | SCIE | – | No |
| 49 | Annual Review of Cancer Biology | 10 | 79th | Q1 | SCIE | – | No |
| 50 | npj Precision Oncology | 9.8 | 78th | Q1 | SCIE | – | Yes |
| 51 | International Journal of Cancer | 9.7 | 78th | Q1 | SCIE | – | No |
| 52 | Molecular Cancer Research | 9.6 | 77th | Q1 | SCIE | – | No |
| 53 | Molecular Therapy Oncology | 9.6 | 77th | Q1 | SCIE | – | Yes |
| 54 | Stem Cell Reviews and Reports | 9.6 | 77th | Q1 | SCIE | – | No |
| 55 | Cancer Immunology, Immunotherapy | 9.5 | 76th | Q1 | SCIE | – | Yes |
| 56 | Molecular Cancer Therapeutics | 9.5 | 76th | Q1 | SCIE | – | No |
| 57 | Molecular Oncology | 9.4 | 75th | Q1 | SCIE | – | Yes |
| 58 | Cancers | 9 | 75th | Q1 | SCIE | – | Yes |
| 59 | Cancer Science | 8.9 | 74th | Q2 | SCIE | – | Yes |
| 60 | Cellular Oncology | 8.6 | 74th | Q2 | SCIE | – | Yes |
| 61 | Cancer Biology and Therapy | 8.4 | 74th | Q2 | SCIE | – | Yes |
| 62 | Advances in Cancer Biology - Metastasis | 8.1 | 73rd | Q2 | ESCI | – | Yes |
| 63 | Breast Cancer Research | 8.1 | 73rd | Q2 | SCIE | – | Yes |
| 64 | Chinese Journal of Cancer Research | 7.9 | 72nd | Q2 | SCIE | – | No |
| 65 | Journal of Gastric Cancer | 7.8 | 72nd | Q2 | SCIE | – | No |
| 66 | Cancer Research and Treatment | 7.7 | 71st | Q2 | SCIE | – | Yes |
| 67 | Oncology Reports | 7.7 | 71st | Q2 | SCIE | – | No |
| 68 | Lung Cancer | 7.4 | 71st | Q2 | SCIE | – | No |
| 69 | Clinical and Experimental Metastasis | 7.4 | 70th | Q2 | SCIE | – | No |
| 70 | Epigenetics | 7.4 | 70th | Q2 | SCIE | – | Yes |
| 71 | Genes and Cancer | 7.3 | 69th | Q2 | – | – | No |
| 72 | Translational Oncology | 7.3 | 69th | Q2 | SCIE | – | Yes |
| 73 | Molecular Medicine Reports | 7.3 | 68th | Q2 | SCIE | – | No |
| 74 | Endocrine-Related Cancer | 7.2 | 68th | Q2 | SCIE | – | No |
| 75 | Advances in Cancer Research | 7 | 68th | Q2 | – | – | No |
| 76 | Targeted Oncology | 6.9 | 67th | Q2 | SCIE | – | No |
| 77 | Oncologist | 6.8 | 67th | Q2 | SCIE | – | Yes |
| 78 | Anti-Cancer Agents in Medicinal Chemistry | 6.7 | 66th | Q2 | SCIE | – | No |
| 79 | Frontiers in Oncology | 6.6 | 66th | Q2 | SCIE | – | Yes |
| 80 | Current Hematologic Malignancy Reports | 6.6 | 65th | Q2 | SCIE | – | No |
| 81 | Nitric Oxide - Biology and Chemistry | 6.6 | 65th | Q2 | SCIE | – | No |
| 82 | PLOS Genetics | 6.6 | 65th | Q2 | SCIE | – | Yes |
| 83 | Journal of Mammary Gland Biology and Neoplasia | 6.5 | 64th | Q2 | SCIE | – | No |
| 84 | Oral Oncology | 6.5 | 64th | Q2 | SCIE | – | No |
| 85 | Cytotherapy | 6.4 | 63rd | Q2 | SCIE | – | No |
| 86 | Seminars in Radiation Oncology | 6.4 | 63rd | Q2 | SCIE | – | No |
| 87 | Journal of Cancer Research and Clinical Oncology | 6.4 | 62nd | Q2 | SCIE | – | Yes |
| 88 | Cancer Pathogenesis and Therapy | 6.2 | 62nd | Q2 | ESCI | – | Yes |
| 89 | Clinical Lung Cancer | 6.2 | 62nd | Q2 | SCIE | – | No |
| 90 | Nutrition and Cancer | 6.2 | 61st | Q2 | SCIE | – | No |
| 91 | Virus Research | 6.2 | 61st | Q2 | SCIE | – | Yes |
| 92 | JCO Precision Oncology | 6.2 | 60th | Q2 | SCIE | – | No |
| 93 | Cancer Cytopathology | 6.1 | 60th | Q2 | SCIE | – | No |
| 94 | Breast Cancer Research and Treatment | 6.1 | 59th | Q2 | SCIE | – | No |
| 95 | Carcinogenesis | 6.1 | 59th | Q2 | SCIE | – | No |
| 96 | JNCI Cancer Spectrum | 6 | 59th | Q2 | ESCI | – | Yes |
| 97 | Genes Chromosomes and Cancer | 6 | 58th | Q2 | SCIE | – | No |
| 98 | NAR Cancer | 5.9 | 58th | Q2 | ESCI | – | Yes |
| 99 | Cancer Biotherapy and Radiopharmaceuticals | 5.9 | 57th | Q2 | SCIE | – | No |
| 100 | Medical Oncology | 5.9 | 57th | Q2 | SCIE | – | No |
| 101 | Analytical Cellular Pathology | 5.8 | 56th | Q2 | SCIE | – | Yes |
| 102 | Human Cell | 5.8 | 56th | Q2 | SCIE | – | No |
| 103 | International Journal of Hyperthermia | 5.7 | 56th | Q2 | SCIE | – | Yes |
| 104 | BMC Cancer | 5.7 | 55th | Q2 | SCIE | – | Yes |
| 105 | Cancer Medicine | 5.7 | 55th | Q2 | SCIE | – | Yes |
| 106 | Molecular Carcinogenesis | 5.6 | 54th | Q2 | SCIE | – | No |
| 107 | Recent Patents on Anti-Cancer Drug Discovery | 5.6 | 54th | Q2 | SCIE | – | No |
| 108 | Journal of Environmental Science and Health, Part C: Toxicology and Carcinogenesis | 5.5 | 53rd | Q2 | SCIE | – | No |
| 109 | Molecular Imaging and Biology | 5.5 | 53rd | Q2 | SCIE | – | No |
| 110 | Cancer Genetics | 5.5 | 52nd | Q2 | SCIE | – | No |
| 111 | Journal of Neuro-Oncology | 5.5 | 52nd | Q2 | SCIE | – | No |
| 112 | Cancer Research Communications | 5.4 | 51st | Q2 | ESCI | – | Yes |
| 113 | Infectious Agents and Cancer | 5.4 | 51st | Q2 | SCIE | – | Yes |
| 114 | Journal of Immunotherapy | 5.4 | 51st | Q2 | SCIE | – | No |
| 115 | Clinical and Translational Oncology | 5.4 | 50th | Q2 | SCIE | – | No |
| 116 | Exploration of Targeted Anti-tumor Therapy | 5.4 | 50th | Q2 | – | – | Yes |
| 117 | Function | 5.3 | 50th | Q2 | ESCI | – | Yes |
| 118 | Advances in Biological Regulation | 5.3 | 49th | Q3 | ESCI | – | No |
| 119 | MedComm - Oncology | 5.3 | 49th | Q3 | ESCI | – | Yes |
| 120 | Tumor Biology | 5.3 | 48th | Q3 | – | – | Yes |
| 121 | Technology in Cancer Research and Treatment | 5.2 | 48th | Q3 | SCIE | – | Yes |
| 122 | Hematological Oncology | 5.2 | 47th | Q3 | SCIE | – | No |
| 123 | Journal of Immunotherapy and Precision Oncology | 5.1 | 47th | Q3 | ESCI | – | Yes |
| 124 | Journal of Oral Pathology and Medicine | 5 | 46th | Q3 | SCIE | – | No |
| 125 | Oncology Reviews | 5 | 46th | Q3 | ESCI | – | Yes |
| 126 | Pathology and Oncology Research | 5 | 46th | Q3 | SCIE | – | Yes |
| 127 | Cancer Treatment and Research Communications | 5 | 45th | Q3 | ESCI | – | Yes |
| 128 | Nuclear Medicine and Biology | 5 | 45th | Q3 | SCIE | – | No |
| 129 | Clinical Breast Cancer | 4.9 | 44th | Q3 | SCIE | – | No |
| 130 | Future Oncology | 4.9 | 44th | Q3 | SCIE | – | No |
| 131 | Cancer Genomics and Proteomics | 4.9 | 43rd | Q3 | SCIE | – | No |
| 132 | Cancer Informatics | 4.9 | 43rd | Q3 | ESCI | – | Yes |
| 133 | Cancer Prevention Research | 4.9 | 43rd | Q3 | SCIE | – | No |
| 134 | JCO Clinical Cancer Informatics | 4.8 | 42nd | Q3 | ESCI | – | No |
| 135 | Neoplasma | 4.8 | 42nd | Q3 | SCIE | – | No |
| 136 | Cell Stress | 4.8 | 41st | Q3 | ESCI | – | Yes |
| 137 | Current Opinion in Oncology | 4.8 | 41st | Q3 | SCIE | – | No |
| 138 | Differentiation | 4.8 | 40th | Q3 | SCIE | – | No |
| 139 | Cancer Journal (United States) | 4.7 | 40th | Q3 | SCIE | – | No |
| 140 | Journal of Breast Cancer | 4.7 | 40th | Q3 | SCIE | – | Yes |
| 141 | Current Problems in Cancer | 4.7 | 39th | Q3 | SCIE | – | No |
| 142 | European Journal of Cancer Prevention | 4.7 | 39th | Q3 | SCIE | – | No |
| 143 | Anti-Cancer Drugs | 4.6 | 38th | Q3 | SCIE | – | No |
| 144 | Cancer Chemotherapy and Pharmacology | 4.6 | 38th | Q3 | SCIE | – | No |
| 145 | Cancer Epidemiology | 4.6 | 37th | Q3 | SCIE | – | No |
| 146 | Brain Tumor Pathology | 4.5 | 37th | Q3 | SCIE | – | No |
| 147 | Aging and Cancer | 4.4 | 37th | Q3 | – | – | Yes |
| 148 | Cancer Innovation | 4.4 | 36th | Q3 | ESCI | – | Yes |
| 149 | JCO Global Oncology | 4.3 | 36th | Q3 | ESCI | – | Yes |
| 150 | Cancer Biomarkers | 4.3 | 35th | Q3 | SCIE | – | No |
| 151 | Current Cancer Drug Targets | 4.2 | 35th | Q3 | SCIE | – | No |
| 152 | International Journal of Breast Cancer | 4.2 | 34th | Q3 | ESCI | – | Yes |
| 153 | International Journal of Biological Markers | 4.1 | 34th | Q3 | SCIE | – | Yes |
| 154 | Oncology Research | 4.1 | 34th | Q3 | SCIE | – | No |
| 155 | JMIR Cancer | 4.1 | 33rd | Q3 | ESCI | – | Yes |
| 156 | Leukemia Research | 4.1 | 33rd | Q3 | SCIE | – | No |
| 157 | Cancer Causes and Control | 4 | 32nd | Q3 | SCIE | – | No |
| 158 | Tumori | 4 | 32nd | Q3 | SCIE | – | No |
| 159 | Experimental Hematology | 4 | 31st | Q3 | SCIE | – | No |
| 160 | Epigenomics | 3.9 | 31st | Q3 | SCIE | – | No |
| 161 | Journal of the National Cancer Institute - Monographs | 3.9 | 31st | Q3 | – | – | No |
| 162 | Leukemia and Lymphoma | 3.9 | 30th | Q3 | SCIE | – | No |
| 163 | Cancer Investigation | 3.7 | 30th | Q3 | SCIE | – | No |
| 164 | Cancer Reports | 3.7 | 29th | Q3 | ESCI | – | Yes |
| 165 | Familial Cancer | 3.7 | 29th | Q3 | SCIE | – | No |
| 166 | Oncology Letters | 3.7 | 29th | Q3 | SCIE | – | No |
| 167 | Japanese Journal of Clinical Oncology | 3.7 | 28th | Q3 | SCIE | – | No |
| 168 | World Journal of Oncology | 3.5 | 28th | Q3 | ESCI | – | No |
| 169 | FASEB BioAdvances | 3.5 | 27th | Q3 | ESCI | – | Yes |
| 170 | Oncology (Switzerland) | 3.5 | 27th | Q3 | SCIE | – | No |
| 171 | Anticancer Research | 3.4 | 26th | Q3 | SCIE | – | No |
| 172 | Breast Cancer: Basic and Clinical Research | 3.4 | 26th | Q3 | ESCI | – | Yes |
| 173 | In Vivo | 3.3 | 25th | Q3 | SCIE | – | No |
| 174 | Journal of the Egyptian National Cancer Institute | 3.2 | 25th | Q3 | ESCI | – | Yes |
| 175 | Melanoma Research | 3.1 | 25th | Q3 | SCIE | – | No |
| 176 | Asian Pacific Journal of Cancer Prevention | 3.1 | 24th | Q4 | – | – | Yes |
| 177 | Biomedical Analysis | 3 | 24th | Q4 | – | – | Yes |
| 178 | Molecular and Cellular Oncology | 3 | 23rd | Q4 | ESCI | – | Yes |
| 179 | Molecular and Clinical Oncology | 3 | 23rd | Q4 | ESCI | – | No |
| 180 | American Journal of Clinical Oncology: Cancer Clinical Trials | 2.7 | 22nd | Q4 | SCIE | – | No |
| 181 | Critical Reviews in Oncogenesis | 2.7 | 22nd | Q4 | – | – | No |
| 182 | Oncology (United States) | 2.7 | 22nd | Q4 | SCIE | – | No |
| 183 | Clinical Lymphoma, Myeloma and Leukemia | 2.6 | 21st | Q4 | SCIE | – | No |
| 184 | Translational Cancer Research | 2.6 | 21st | Q4 | SCIE | – | No |
| 185 | Breast Disease | 2.5 | 20th | Q4 | – | – | No |
| 186 | Cancer Diagnosis and Prognosis | 2.5 | 20th | Q4 | – | – | No |
| 187 | Precision Cancer Medicine | 2.5 | 19th | Q4 | – | – | No |
| 188 | Oncology Research and Treatment | 2.4 | 19th | Q4 | SCIE | – | No |
| 189 | Cancer Treatment and Research | 2.3 | 19th | Q4 | – | – | No |
| 190 | ecancermedicalscience | 2.1 | 18th | Q4 | ESCI | – | Yes |
| 191 | Prostate Cancer | 2.1 | 18th | Q4 | ESCI | – | Yes |
| 192 | Asian Pacific Journal of Cancer Biology | 1.9 | 17th | Q4 | – | – | Yes |
| 193 | Discover Oncology | 1.9 | 17th | Q4 | SCIE | – | Yes |
| 194 | Bulletin du Cancer | 1.6 | 16th | Q4 | SCIE | – | No |
| 195 | Chinese Journal of Lung Cancer | 1.6 | 16th | Q4 | – | – | Yes |
| 196 | World Cancer Research Journal | 1.6 | 16th | Q4 | ESCI | – | Yes |
| 197 | Recent Results in Cancer Research | 1.6 | 15th | Q4 | – | – | No |
| 198 | Nowotwory | 1.5 | 15th | Q4 | – | – | Yes |
| 199 | Experimental Oncology | 1.4 | 14th | Q4 | – | – | No |
| 200 | Current Cancer Therapy Reviews | 1.3 | 14th | Q4 | ESCI | – | No |
| 201 | Asian Journal of Natural Product Biochemistry | 1.3 | 13th | Q4 | – | – | No |
| 202 | Archives of Breast Cancer | 1.1 | 13th | Q4 | – | – | No |
| 203 | South Asian Journal of Cancer | 1 | 13th | Q4 | ESCI | – | Yes |
| 204 | Endocrine Oncology | 1 | 12th | Q4 | ESCI | – | Yes |
| 205 | International Journal of Cancer Management | 0.9 | 12th | Q4 | ESCI | – | No |
| 206 | International Journal of Medical Biochemistry | 0.9 | 11th | Q4 | ESCI | – | Yes |
| 207 | Middle East Journal of Cancer | 0.9 | 11th | Q4 | ESCI | – | Yes |
| 208 | Annals of Cancer Research and Therapy | 0.8 | 10th | Q4 | – | – | No |
| 209 | NTP Technical Report on the Toxicity Studies Series | 0.8 | 10th | Q4 | – | – | No |
| 210 | RNA Technologies | 0.8 | 10th | Q4 | – | – | No |
| 211 | Clinical and Experimental Morphology | 0.7 | 9th | Q4 | – | – | No |
| 212 | Siberian Journal of Oncology | 0.7 | 9th | Q4 | – | – | Yes |
| 213 | IARC Monographs on the Evaluation of Carcinogenic Risks to Humans | 0.6 | 8th | Q4 | – | – | No |
| 214 | Journal of Modern Oncology | 0.6 | 8th | Q4 | – | – | Yes |
| 215 | Journal of Cancer Research Updates | 0.6 | 7th | Q4 | – | – | No |
| 216 | Uspehi Molekularnoj Onkologii | 0.6 | 7th | Q4 | – | – | No |
| 217 | Voprosy Onkologii | 0.6 | 7th | Q4 | – | – | No |
| 218 | Chinese Journal of Biochemistry and Molecular Biology | 0.5 | 6th | Q4 | – | – | No |
| 219 | Opuholi Golovy i Sei | 0.5 | 6th | Q4 | – | – | No |
| 220 | Cancer Drug Discovery and Development | 0.5 | 5th | Q4 | – | – | No |
| 221 | SciEnggJ | 0.5 | 5th | Q4 | – | – | No |
| 222 | Cancer Research on Prevention and Treatment | 0.4 | 4th | Q4 | – | – | Yes |
| 223 | Rossijskij Bioterapevticeskij Zurnal | 0.4 | 4th | Q4 | – | – | No |
| 224 | Journal of Practical Oncology | 0.3 | 4th | Q4 | – | – | No |
| 225 | Chinese Journal of Clinical Oncology | 0.3 | 3rd | Q4 | – | – | No |
| 226 | Gaceta Mexicana de Oncologia | 0.3 | 3rd | Q4 | ESCI | – | Yes |
| 227 | Chinese Journal of Cancer Biotherapy | 0.2 | 2nd | Q4 | – | – | No |
| 228 | Tumor | 0.2 | 2nd | Q4 | – | – | No |
| 229 | Cancer Research and Clinic | 0.1 | 1st | Q4 | – | – | No |
| 230 | Japanese Journal of Cancer and Chemotherapy | 0.1 | 1st | Q4 | – | – | No |
| 231 | Journal of Leukemia and Lymphoma | 0.1 | 1st | Q4 | – | – | No |
| 232 | Journal of B.U.ON. | 0 | 0th | Q4 | – | – | No |
| 233 | Onkologie (Czech Republic) | 0 | 0th | Q4 | – | – | No |
Rank and percentile are within the Cancer Research Scopus subject table (CiteScore 2025, dataset 2026-10-04). A journal can rank differently in its other subject areas — open its profile for the full picture.